EXHIBIT 5.1
January 4, 2021
Prelude Therapeutics Incorporated
200 Powder Mill Road
Wilmington, Delaware 19803
Ladies and Gentlemen:
At your request, we have examined the Registration Statement on Form S-1 (the “Registration Statement”) initially filed by Prelude Therapeutics Incorporated, a Delaware corporation (the “Company”), with the Securities and Exchange Commission (the “Commission”) on or about January 4, 2021, in connection with the registration under the Securities Act of 1933, as amended (“Securities Act”), of an aggregate of 2,012,500 shares of the Company’s common stock (including up to 262,500 shares subject to the underwriters’ option to purchase additional shares) (the “Shares”), consisting of the Company’s voting common stock, par value $0.0001 per share (the “Common Stock”), and, to the extent Shares are purchased by certain existing stockholders of the Company, including by entities affiliated with certain of the Company’s directors, the Company’s non-voting common stock, par value $0.0001 per share (the “Non-Voting Common Stock”).
In connection with our opinion expressed below we have examined originals or copies of the underwriting agreement pursuant to which the Shares will be sold to the underwriters, the Registration Statement, the prospectus prepared in connection with the Registration Statement (the “Prospectus”), the Company’s Restated Certificate of Incorporation (the “Certificate”), and the Company’s Restated Bylaws (the “Bylaws”), certain minutes and consents of the Company’s board of directors (the “Board”) or a committee or committees thereof and the Company’s stockholders relating to the Registration Statement, the Certificate and the Bylaws, and such other agreements, documents, certificates and statements of the Company, its transfer agent and public or government officials, as we have deemed advisable, and have examined such questions of law as we have considered necessary. In giving our opinion, we have also relied upon a good standing certificate regarding the Company issued by the Delaware Secretary of State and a management certificate addressed to us and dated of even date herewith executed by the Company containing certain factual representations by the Company.
In our examination of documents for purposes of this opinion, we have assumed, and express no opinion as to, the genuineness of all signatures on original documents, the authenticity and completeness of all documents submitted to us as originals, the conformity to originals and completeness of all documents submitted to us as copies, the legal capacity of all persons or entities executing the same (other than the Company), the lack of any undisclosed termination, modification, waiver or amendment to any document reviewed by us.
We render this opinion only with respect to, and express no opinion herein concerning the application or effect of the laws of any jurisdiction other than, the existing Delaware General Corporation Law.
In connection with our opinion expressed below, we have assumed that, at or prior to the time of the delivery of any shares of Shares, the Registration Statement will have been declared effective under the Securities Act that the registration will apply to the offer and sale of such shares of Shares and will not have been modified or rescinded and that there will not have occurred any change in law affecting the validity of the issuance of such shares of Shares.
Based upon the foregoing, we are of the opinion that the up to 2,012,500 Shares that may be issued and sold by the Company, when issued, sold and delivered in the manner and for the consideration stated in the Registration Statement